Sight Sciences, Inc. (SGHT)
Nasdaq · Healthcare · Medical Devices
$8.92+4.57%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $491M
- 52-week range
- $3.19 – $9.71
- 52-week change
- +145.82%
- EPS (trailing)
- −$0.56
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $77.4M (−3.13%)
- Net income
- −$38.4M
- Operating margin
- −48.0%
- Diluted EPS
- −$0.74
- Free cash flow
- −$29.9M
From the company’s annual report on SEC EDGAR.
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists.
Headquarters: Menlo Park, United States · 186 employees · sightsciences.com